Table 3.
Impact of 68Ga-DOTA-peptide PET/CT on the surveillance and monitoring response post-chemo/sandostatin/everolimus/PRRT (n = 36)
| PET/CT showed progression | 17 (47.2%) |
| PET/CT showed non-progression | 19 (52.8%) |
| Impact on therapy | 19 (52.8%) |
| Start octreotide Increase octreotide dosage Start chemotherapy Start everolimus Start PRRT |
2 3 4 3 7 |
| No impact on therapy | 16 (44.4%) |
| Continue sandostatin dosage Continue everolimus Continue PRRT |
11 1 4 |
| Unknown impact because lost to follow-up | 1 (2.8%) |